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1. Introduction 
Coronary heart disease (CHD) is one of the major causes of death in adults in the 
developed and developing countries which is referred to the condition in which the main 
coronary arteries supplying the heart are no longer able to supply sufficient blood and 
oxygen to the heart muscle (myocardium). The main cause of the reduced flow is an 
accumulation of plaques, mainly in the intima of arteries, a disease known as 
atherosclerosis (Akbarzadeh and Toufan, 2008). A number of risk factors known to affect 
an individual to CHD have been categorized such as hyperlipidaemia (high levels of 
lipids in the blood), hypertension (high blood pressure), obesity, cigarette smoking and 
lack of exercise. Probiotics as a live microbial food supplement beneficially affects the host 
by improving its intestinal microbial balance and is generally consumed as fermented 
milk products containing lactic acid bacteria such as bifidobacteria and/or lactobacilli. The 
supposed health benefits of probiotics include improved resistance to gastrointestinal 
infections, reduction in total cholesterol and TAG levels and stimulation of the immune 
system. A number of mechanisms have been proposed to explain their putative lipid-
lowering capacity and these include a ‘milk factor’, which has been thought to inhibit 
HMG-CoA reductase and the assimilation of cholesterol by certain bacteria. The 
mechanism of action of probiotics on cholesterol reduction include physiological actions 
of the end products of fermentation SCFAs, cholesterol assimilation, deconjugation of bile 
acids and cholesterol binding to bacterial cell walls. It has been well documented that 
microbial bile acid metabolism is a peculiar probiotic effect involved in the therapeutic 
role of some bacteria. The deconjugation reaction is catalyzed by conjugated bile acid 
hydrolase enzyme, which is produced exclusively by bacteria. The mechanism of 
cholesterol binding to bacterial cell walls has also been suggested as a possible 
explanation for hypocholesterolaemic effects of probiotics. Probiotics have received 
attention for their beneficial effects on the gut microflora and links to their systemic 
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effects on the lowering of lipids known to be risk factors for CHD, notably cholesterol and 
TAG. The incorporation of probiotics into dairy products such as fermented milk 
products controlled nutrition studies need to be carried out to determine the beneficial 
effects of prebiotics, probiotics and synbiotics before substantial health claims can be 
made (Ranjbar et al., 2007a). 
2. Probiotics 
Probiotics are distinct as live microorganisms which, when administered in sufficient 
amounts present a health benefit on the host (FAO/WHO, 2002; Homayouni, 2008a; 
Homayouni, 2009). In recent years probiotic bacteria have increasingly been incorporated 
into dairy foods as dietary adjuncts. Lactobacillus and Bifidobacterium are the most common 
species of probiotic bacteria that were used in the production of fermented and non-
fermented dairy products. Consumption of probiotic bacteria via dairy food products is an 
ideal way to re-establish the intestinal microflora balance (Homayouni, 2008a). 
Probiotics have been shown to be effective against a number of disorders. Some mostly 
documented effects are relieving diarrhea, improving lactose intolerance and its 
immunomodulatory, anticarcinogenic, antidiabetic, hypocholesterolemic and hypotensive 
properties (Shah, 2007; Mai, and Draganov, 2009; Lye, et al., 2009). Probiotic bacteria, by 
competing with enteric pathogens for available nutrients and binding sites, reducing the pH 
of the gut, producing a variety of chemicals which inactivate viruses, enhancing specific and 
non-specific immune responses and increasing mucin production, can reduce incidence, 
severity and duration of diarrhea (Homayouni, et al., 2007; Allen, et al., 2010; Ejtahed, and 
Homayouni Rad, 2010). Alleviation of lactose intolerance symptoms by probiotic bacteria is 
attributed to their intracellular β-galactosidase content (Mustapha, et al., 1997). Studies have 
revealed that probiotic bacteria can induce many immunological changes and affect both 
Th1 and Th2 cytokine production and that these effects are strongly strain-specific (Lebeer, 
et al., 2010). Some major routes through which probiotic bacteria have been assumed to 
prevent cancer are: binding to mutagenic compounds thus decreasing their absorption, 
suppression of the growth of bacteria which convert procarcinogens to carcinogens, 
decreasing the activity of enzymes predictive of neoplasm including β-glucuronidase, 
nitroreductase and choloylglycine hydrolase as well as enhancing immune responses (Roos, 
and Katan, 2000). Inflammation plays a major role in both initiation and progression of 
diabetes (Duncan, et al., 2003; Pickup, and Frcpath, 2004). By reducing inflammatory 
responses, probiotics have been shown to correct insulin sensitivity and reduce 
development of diabetes mellitus. This anti-inflammatory effect has been proposed to be 
rooted in immunomodulatory properties of probiotic bacteria (Lye, et al., 2009). By reducing 
cholesterol absorption in the gut, incorporation of cholesterol into cell membranes, 
enzymatically deconjugation of bile salts and conversion of cholesterol to coprostanol, 
probiotics can reduce blood cholesterol (Lye, et al., 2009; Ooi, and Liong, 2010). Release of 
angiotensin converting enzyme (ACE) inhibitory peptides from the parent protein through 
proteolytic action explains how probiotics can exert antihypertensive effects (Lye, et al., 
2009). 
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3. Dairy probiotic foods 
Dairy probiotic foods are scientifically documented as having physiological benefits beyond 
those of basic nutritional values. Dairy products such as ice cream, cheese, yogurt, 
acidophilus-bifidus-milk, ayran, kefir, kumis, doogh containing probiotics and milk having 
omega-3, phytosterols, isoflavins, CLA, minerals, and vitamins have an outstanding position 
in the development of functional foods (Homayouni, et al., 2008b; Homayouni, et al., 2008c). 
Dairy beverages (both fermented and non-fermented) have long been considered as 
important vehicles for the delivery of probiotics. In fermentation process, lactic acid, acetic 
acid and citric acid are naturally produced which are commonly used organic acids to 
enhance organoleptic qualities as well as safety of many food products. Lactic acid bacteria 
are found to be more tolerant to acidity and organic acids than most of the pathogens and 
spoilage microorganisms (Homayouni, et al., 2008d).  
4. Coronary heart disease (CHD) 
Coronary heart disease (CHD) is one of the major causes of death in adults in the developed 
and developing countries which is referred to the condition in which the main coronary 
arteries supplying the heart are no longer able to supply sufficient blood and oxygen to the 
heart muscle (myocardium). The main cause of the reduced flow is an accumulation of 
plaques, mainly in the intima of arteries, a disease known as atherosclerosis (Akbarzadeh 
etal., 2003; Ranjbar et al., 2007b; Akbarzadeh etal., 2010; Ghaffari etal., 2010). 
5. Main risk factors of coronary heart disease 
CHD has assumed almost epidemic proportions in wealthy societies, whereas rheumatic 
heart disease is common in developing countries (Akbarzadeh etal., 2003; Akbarzadeh etal., 
2008). Known risk factors of CHD can be classified into those that cannot be modified (being 
male increasing age, genetic traits including lipid metabolism abnormalities, body build, 
ethnic origin), those that can be changed (cigarette smoking, hyperlipidaemia, low levels of 
high density lipoprotein, obesity, hypertension, low physical activity, increased thrombosis, 
stress, alcohol consumption), those associated with disease states (diabetes and glucose 
intolerance) and those related to geographic distribution (climate and season, cold weather, 
soft drinking water) (Lovegrove and Jackson, 2003; Akbarzadeh etal., 2009a). It has been 
demonstrated that there is a strong and consistent relationship between total plasma 
cholesterol and CHD risk (Martin et al., 1986). Accumulation of LDL in the plasma leads to a 
deposition of cholesterol in the arterial wall, a process that involves oxidative modification 
of the LDL particles. The oxidized LDL is taken up by macrophages, which finally become 
foam cells and forms the basis of the early atherosclerotic plaque. It has been estimated that 
every 1% increase in LDL cholesterol level leads to a 2-3% increase in CHD risk (Gensini et 
al., 1998; Akbarzadeh etal., 2009b). HDL cholesterol levels are higher in women than in men. 
Factors that may lead to reduced HDL cholesterol levels include smoking, low physical 
activity and diabetes mellitus; whereas those that increase levels include moderate alcohol 
consumption (Assmann et al., 1998; Akbarzadeh etal., 2009c). 
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6. Probiotics and CHD: Mechanism of action 
Diet is considered to control the risk of CHD through its effects on certain risk factors 
including blood lipids, blood pressure and probably also through thrombogenic 
mechanisms. New evidences suggest a protective role for dietary antioxidants such as 
vitamins E and C and carotenes, possibly through a mechanism that prevents the oxidation 
of LDL cholesterol particles (Lovegrove and Jackson, 2003). The diet is one of the adjustable 
risk factors associated with CHD risk which is recommends to reduce total fat (especially 
saturated fat), increasing Non-starch polysaccharides (NSP) intake and consumption of fruit 
and vegetables is advice that is expected to be associated with overall benefits on health. 
As a result of low consumer compliance of low-fat diets, attempts have been made to 
identify other dietary components that can reduce blood cholesterol levels. These have 
included investigations into the possible hypocholesterolaemic properties of milk products, 
especially in a fermented form. 18% fall in plasma cholesterol after feeding 4-5 liters of 
fermented milk per day for three weeks (Mann, and Spoerry, 1974). 
The mechanisms of action of probiotics on cholesterol reduction are physiological actions of 
the end products of fermentation SCFAs, cholesterol assimilation, deconjugation of bile 
acids and cholesterol binding to bacterial cell walls. The SCFAs that are produced by the 
bacterial anaerobic breakdown of carbohydrate are acetic, propionic and butyric. It has been 
well documented that microbial bile acid metabolism is a irregular probiotic effect involved 
in the therapeutic role of some bacteria. The deconjugation reaction is catalyzed by 
conjugated bile acid hydrolase enzyme, which is produced exclusively by bacteria. 
Deconjugation ability is widely found in many intestinal bacteria including genera 
Enterococcus, Peptostreptococcus, Bifidobacterium, Fusobacterium, Clostridium, 
Bacteroides and Lactobacillus (Hylemond, 1985). This reaction releases the amino acid 
moiety and the deconjugated bile acid, thereby reducing cholesterol reabsorption, by 
increasing faecal excretion of the deconjugated bile acids. Many in vitro studies have 
investigated the ability of various bacteria to deconjugate a variety of different bile acids. 
Grill et al. (1995) reported Bifidobacterium longum as the most efficient bacterium when 
tested against six different bile salts. Another study reported that Lactobacillus species had 
varying abilities to deconjugate glycocholate and taurocholate (Gilliland et al., 1985). Studies 
performed on in vitro responses are useful but in vivo studies in animals and humans are 
required to determine the full contribution of bile acid deconjugation to cholesterol 
reduction. Intervention studies on animals and ileostomy patients have shown that oral 
administration of certain bacterial species led to an increased excretion of free and 
secondary bile salts (De Smet, et al., 1998; Marteau, et al., 1995). 
There is also some in vitro evidence to support the hypothesis that certain bacteria can 
assimilate (take up) cholesterol. It was reported that L. acidophilus and B. bifidum had the 
ability to assimilate cholesterol in in vitro studies, but only in the presence of bile and under 
anaerobic conditions (Gilliland, et al., 1985; Rasic, et al., 1992). However, despite these 
reports there is uncertainty whether the bacteria are assimilating cholesterol or whether the 
cholesterol is co-precipitating with the bile salts. Studies have been performed to address 
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this question. Klaver and Meer (1993) concluded that the removal of cholesterol from the 
growth medium in which L. acidophilus and a Bifidobacterium sp. were growing was not 
due to assimilation, but due to bacterial bile salt deconjugase activity. The same question 
was addressed by Tahri et al., (1995) with conflicting results, and they concluded that part of 
the removed cholesterol was found in the cell extracts and that cholesterol assimilation and 
bile acid deconjugase activity could occur simultaneously. 
The mechanism of cholesterol binding to bacterial cell walls has also been suggested as a 
possible explanation for hypocholesterolaemic effects of probiotics. Hosona and Tono-oka 
(1995) reported Lactococcus lactis subsp. biovar had the highest binding capacity for 
cholesterol of bacteria tested in the study. It was speculated that the binding differences 
were due to chemical and structural properties of the cell walls, and that even killed cells 
may have the ability to bind cholesterol in the intestine. The mechanism of action of 
probiotics on cholesterol reduction could be one or all of the above mechanisms with the 
ability of different bacterial species to have varying effects on cholesterol lowering. 
However, more research is required to elucidate fully the effect and mechanism of 
probiotics and their possible hypocholesterolaemic action.  
It has been demonstrated that microbial bile acid metabolism is a main effect in the 
therapeutic role of probiotic bacteria. The deconjugation reaction is catalysed by conjugated 
bile acid hydrolase enzyme, which is produced by Bifidobacterium and Lactobacillus. This 
reaction releases the amino acid and deconjugated bile acid, which is reducing cholesterol 
reabsorption, by increasing faecal elimination of the deconjugated bile acids. 
7. Conclusions and future trends 
Risk factors known to affect an individual to CHD have been categorized such as 
hyperlipidaemia, hypertension, obesity, cigarette smoking and lack of exercise. Probiotics 
may prevent coronary heart disease by cholesterol reduction and microbial bile acid 
metabolism. The mechanism of action of probiotics on cholesterol reduction include 
physiological actions of the end products of fermentation SCFAs, cholesterol assimilation, 
deconjugation of bile acids and cholesterol binding to bacterial cell walls. It has been 
demonstrated that microbial bile acid metabolism is a peculiar probiotic effect involved in 
the therapeutic role of some bacteria. Deconjugation reaction is catalyzed by conjugated 
bile acid hydrolase enzyme, which is produced exclusively by bacteria. The mechanism of 
cholesterol binding to bacterial cell walls has also been suggested as a possible 
explanation for hypocholesterolaemic effects of probiotics. Probiotics have beneficial 
effects on the gut microflora and links to their systemic effects on the lowering of lipids 
known to be risk factors for CHD, notably cholesterol and TAG. In recent years, several 
probiotic foods were produced industrially. These foods have received attention for their 
beneficial effects on the gut microflora and links to their systemic effects on the lowering 
of lipids known to be risk factors for CHD. For progress to be made, the consumers need 
to be educated about the various health benefits and how they will be able to use these 
products in their own diet without adverse consequences. Also to make these foods 
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attractive to the consumer, the products need to be priced in such a way that they are 
accessible to the general public. 
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